KERYX ACQUIRES DIAGNOSTIC FOR MICROALBUMINURIA DETECTION
Keryx Biopharmaceuticals has entered into an agreement to acquire Accumin, a diagnostic for the measurement of intact urinary albumin from AusAm Biotechnologies. Accumin identifies abnormal levels of albumin in urine from patients with kidney disease.
In patients with diabetes, the earliest clinical evidence of diabetic nephropathy or diabetic kidney disease, is the appearance of microalbuminuria.
The purchase agreement is subject to closing, which is expected to occur on or before April 5, 2006.